ProKidney Corp. faces weak Phase 2 rilparencel data and a cash runway only to mid-2027 ahead of pivotal 2027 Phase 3 results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results